MOUNTAIN VIEW, Calif., May 5 (UPI) -- Vivus said Friday it has seen positive results from a study of Evamist, the first transdermal spray for menopause symptoms.
The company said findings from its phase 3 trial of the novel treatment show a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested.
The once-daily therapy, which delivers the naturally occurring estrogen hormone estradiol, is being studied for the treatment of vasomotor symptoms associated with menopause.
Vivus' 12-week study, conducted at 43 U.S. clinical sites in the United States, tested the drug in three treatment groups, each administering a different dose with one, two or three sprays.
The study results showed that the most effective dose significantly decreased the number of hot flashes by 78 percent, from 10.7 hot flashes per day at baseline to 2.3 hot flashes after treatment, Vivus said.
